Articles from Syneos Health, Inc.

Scaling People Practices for High Performance

Colin Shannon Appointed Executive Chairman

Honored for Notable Biopharmaceutical Industry Impact

Katie Mahony and Sushma Prakash Honored for Purpose-Driven Leadership

Survey Shows Increased Dealmaking Focus on Antibody-Drug Conjugates, Generative AI Products and Cell & Gene Therapies

Generative AI Poised to Reinvent Life Sciences, Leading to Profound Changes in Healthcare

Industry Veteran Brings Decades of Experience Driving Growth at Global Biopharmaceutical Solutions Organizations

Transaction Will Drive Ongoing Transformation and Accelerate Delivery of Tech-Enabled, Fit-for-Purpose Solutions to Biopharma Customers

Industry Veteran to Play Critical Role in Leading Global Clinical Operations, Cultivating Site Relationships, Empowering Patients and Shaping Innovative Clinical Trial Solutions

MORRISVILLE, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic collaboration that will expand its relationship with Oracle. Using the Oracle Cerner Learning Health Network (LHN) and elements of Oracle’s suite of study startup solutions, the companies seek to help reduce the time it takes to recruit patients for clinical studies and increase the diversity of patient populations participating in medical research.

MORRISVILLE, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Star Parent, Inc. (the “Issuer” or the “Company”) and Syneos Health, Inc. (“Syneos Health”), announced today that, subject to market conditions and other factors, the Issuer intends to offer $1,700,000,000 aggregate principal amount of Senior Secured Notes due 2030 (the “Notes”). The Issuer intends to use the proceeds from the offering together with other financing sources to fund the previously announced acquisition of Syneos Health (the “Acquisition”) by the Issuer and certain of its affiliated entities (such affiliates, together with the Issuer, the “Purchasing Entities”) and related refinancings. The Purchasing Entities were newly-formed entities established by a consortium of private investment funds led by Elliott Investment Management L.P. and its affiliates, Patient Square Capital, LP and its affiliates and Veritas Capital Fund Management, L.L.C. and its affiliates. If the sale of the Notes is not completed concurrently with the closing of the Acquisition, then the proceeds from the sale of the Notes will be placed into escrow until the closing of the Acquisition. 

MORRISVILLE, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today announced that the Company’s stockholders approved an agreement to take the Company private through an acquisition by a consortium of private investment firm affiliates comprised of Elliott Investment Management L.P., Patient Square Capital, and Veritas Capital at a special meeting of stockholders held earlier today. As previously announced, under the terms of the agreement, Syneos Health stockholders will receive $43.00 in cash for each share of Syneos Health common stock owned at the closing of the transaction, if completed.

Human Resources Leader with Nearly 30 Years of Experience and Commitment to Professional Services Environment

Integrated eCOA & ePRO Solution Taps Company’s Decentralized Capabilities and Technology Expertise

Newly Created Role Demonstrates Commitment to Improve Diversity in Clinical Trials and Commercialization Across Organization

Healthcare Businesswomen’s Association Spotlights Jennifer Sozio and Caitlin Purinai for Biopharma Industry Impact

Company Executives Honored for Notable Biopharmaceutical Industry Impact

MORRISVILLE, N.C., May 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today reported financial results for the three months ended March 31, 2023.

Shareholders to Receive $43.00 Per Share in Cash

Finance Leader with 30+ Years of Experience, Including 15 Years in Clinical Research Industry

MORRISVILLE, N.C., April 13, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, will release its first quarter 2023 financial results on Wednesday, May 10th, 2023, prior to its earnings call at 8:00 a.m. ET.

Company Recognized for Positive Vaccine Expertise Contributions

MORRISVILLE, N.C., April 04, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced Jeanine O’Kane as President of Syneos Health Communications — a portfolio of agencies spanning advertising, public relations, patient advocacy, medical communications, managed markets, and naming and branding. Formally President of the US Public Relations Group at Syneos Health Communications, Jeanine has been with the organization for more than a decade and has more than 20 years of industry experience.

Program Drives Digital and Omnichannel Engagement for Medical Science Liaison Teams & Medical Conferences

Collaboration Will Leverage Data Analytics and AI to Accelerate Clinical Trial Execution

Collaboration Leverages AI-ready Technology to Speed Asset Development and Optimize Performance

Newly Established Network Will Enable High Quality DCTs & Digital Health Technology Solutions

MORRISVILLE, N.C., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today reported financial results for the three months and year ended December 31, 2022.

MORRISVILLE, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its fourth quarter and full year 2022 financial results on Thursday, February 16, 2023, prior to its earnings call at 8:00 a.m. ET.

MORRISVILLE, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Equicare to use proXimity™, an innovative cloud-based software platform that accelerates the transfer of clinical trial subject data from multiple electronic health records (EHR) to the sponsor’s electronic data capture systems (EDC).

Combined Capabilities Will Help Improve Trial Lifecycles for Patients, Sites & Sponsors

Relationship Will Leverage Syneos One Expertise, Accessing Clinical and Commercial Solutions

Despite Uncertainties, Survey Hints that Dealmaking Intensity Could Be Poised for a Rebound After a Year of Inertia

Reaffirms Full-Year 2022 Revenue Guidance

MORRISVILLE, N.C., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Michelle Keefe is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 10:30 a.m. EST. The Company will not be hosting investor meetings.

Continued Collaboration Will Accelerate Bringing Clinical Trials Closer to the Patient

Predicts AI and Machine Learning, Diversity and Medical Affairs will Transform Biopharma Product Development

MORRISVILLE, N.C., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Michelle Keefe is scheduled to participate in a fireside chat at the 2022 Evercore ISI HealthCONx Conference on December 1, 2022, at 7:00 a.m. ET. The Company will not be hosting investor meetings.

MORRISVILLE, N.C., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today reported financial results for the three and nine months ended September 30, 2022.

Brings Together the Industry’s Most Comprehensive Suite of Modular Patient Services, Optimizing Patient Experience from Prescription to Adherence

MORRISVILLE, N.C., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its third quarter 2022 financial results on Friday, November 4, 2022, prior to its earnings call at 8:00 a.m. ET.

MORRISVILLE, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of William E. Klitgaard to its Board of Directors. Mr. Klitgaard was previously a member of the Syneos Board from 2017 until May 2022, having resigned due to a personal matter. The Company also announced today that Todd M. Abbrecht is stepping down from its Board of Directors.

MORRISVILLE, N.C., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it has been awarded a Triangle Business Journal 2022 Leaders in Diversity Award for notable accomplishments in the field of Diversity, Equity & Inclusion (DE&I). The Company was recognized for its DE&I programs and strong focus on building a culture that values diversity of thought, experiences, perspectives and backgrounds.  

Collaboration Streamlines Clinical Trial Tokenization, Further Empowers Medical Affairs, Market Access, HEOR and Commercial Analytics for Clients

Report Spotlights Significant Progress Toward Achieving Company’s Environmental, Social and Governance Goals, Including Climate Pledge and DE&I Objectives